

# Shaji K Kumar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/187840/publications.pdf>

Version: 2024-02-01

1,161  
papers

66,332  
citations

807

118  
h-index

1456

220  
g-index

1178  
all docs

1178  
docs citations

1178  
times ranked

29803  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
2	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008, 111, 2516-2520.	0.6	2,022
3	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
4	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
5	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. <i>Leukemia</i> , 2014, 28, 1122-1128.	3.3	1,128
6	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	3.3	1,023
7	Promiscuous Mutations Activate the Noncanonical NF- $\kappa$ B Pathway in Multiple Myeloma. <i>Cancer Cell</i> , 2007, 12, 131-144.	7.7	941
8	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. <i>Blood</i> , 2009, 113, 5412-5417.	0.6	904
9	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	13.9	861
10	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	7.7	847
11	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. <i>Journal of Clinical Oncology</i> , 2012, 30, 989-995.	0.8	837
12	Multiple myeloma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17046.	18.1	812
13	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549.	0.8	735
14	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	13.9	684
15	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
16	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. <i>Blood</i> , 2005, 106, 4050-4053.	0.6	604
17	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
18	Clonal competition with alternating dominance in multiple myeloma. <i>Blood</i> , 2012, 120, 1067-1076.	0.6	575

#	ARTICLE	IF	CITATIONS
19	Mesenteric Venous Thrombosis. <i>New England Journal of Medicine</i> , 2001, 345, 1683-1688.	13.9	558
20	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
21	Multiple Myeloma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2016, 91, 101-119.	1.4	473
22	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	1.4	440
23	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. <i>Leukemia</i> , 2009, 23, 1545-1556.	3.3	428
24	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. <i>Blood</i> , 2017, 130, 2401-2409.	0.6	403
25	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , 2012, 119, 4375-4382.	0.6	396
26	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	5.1	394
27	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. <i>New England Journal of Medicine</i> , 2018, 378, 241-249.	13.9	392
28	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1095-1110.	1.4	389
29	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	3.3	385
30	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	0.6	377
31	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. <i>Blood</i> , 2008, 111, 785-789.	0.6	355
32	Clinical Course of Patients With Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2004, 79, 867-874.	1.4	319
33	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. <i>Leukemia</i> , 2007, 21, 2035-2042.	3.3	317
34	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. <i>Lancet</i> , The, 2010, 375, 1721-1728.	6.3	313
35	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. <i>British Journal of Haematology</i> , 2005, 128, 192-203.	1.2	305
36	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. <i>Leukemia</i> , 2013, 27, 780-791.	3.3	294

#	ARTICLE	IF	CITATIONS
37	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology, The</i> , 2019, 20, e302-e312.	5.1	290
38	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5008-5014.	0.8	286
39	Malignant primary cardiac tumors. <i>Cancer</i> , 2008, 112, 2440-2446.	2.0	276
40	Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. <i>Cancer Research</i> , 2006, 66, 184-191.	0.4	266
41	The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. <i>Blood</i> , 2007, 109, 465-470.	0.6	259
42	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448.	3.3	259
43	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014, 15, 333-342.	5.1	256
44	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
45	Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis. <i>Mayo Clinic Proceedings</i> , 2014, 89, 484-492.	1.4	244
46	Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target. <i>Cancer Cell</i> , 2009, 16, 309-323.	7.7	242
47	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1630-1642.	5.1	237
48	Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. <i>Cancer Research</i> , 2007, 67, 2982-2989.	0.4	236
49	Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1 $\beta$ -Induced Interleukin 6 Production and the Myeloma Proliferative Component. <i>Mayo Clinic Proceedings</i> , 2009, 84, 114-122.	1.4	236
50	Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. <i>Leukemia</i> , 2018, 32, 252-262.	3.3	234
51	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology, The</i> , 2014, 15, 1503-1512.	5.1	233
52	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2006, 107, 3378-3383.	0.6	230
53	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. <i>Blood</i> , 2017, 130, 2392-2400.	0.6	229
54	Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. <i>Blood Advances</i> , 2017, 1, 282-287.	2.5	228

#	ARTICLE	IF	CITATIONS
55	Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. Mayo Clinic Proceedings, 2006, 81, 1047-1053.	1.4	221
56	Thalidomide as initial therapy for early-stage myeloma. Leukemia, 2003, 17, 775-779.	3.3	219
57	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 2012, 119, 2100-2105.	0.6	218
58	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia, 2014, 28, 525-542.	3.3	214
59	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia, 2009, 23, 1904-1912.	3.3	207
60	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia, 2016, 30, 1005-1017.	3.3	204
61	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood, 2009, 114, 1729-1735.	0.6	203
62	The multiple myelomas " current concepts in cytogenetic classification and therapy. Nature Reviews Clinical Oncology, 2018, 15, 409-421.	12.5	203
63	Hepatic Veno-occlusive Disease (Sinusoidal Obstruction Syndrome) After Hematopoietic Stem Cell Transplantation. Mayo Clinic Proceedings, 2003, 78, 589-598.	1.4	202
64	Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia, 2013, 27, 941-946.	3.3	201
65	Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood, 2015, 125, 443-448.	0.6	195
66	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia, 2013, 27, 1738-1744.	3.3	194
67	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood, 2011, 118, 2970-2975.	0.6	193
68	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	0.8	193
69	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia, 2007, 21, 529-534.	3.3	191
70	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1228-1263.	0.8	190
71	The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19478-19483.	3.3	189
72	Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney. Journal of the American Society of Nephrology: JASN, 2011, 22, 1129-1136.	3.0	188

#	ARTICLE	IF	CITATIONS
73	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. <i>Blood</i> , 2014, 124, 1047-1055.	0.6	185
74	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). <i>Leukemia</i> , 2010, 24, 1934-1939.	3.3	182
75	Multiple myeloma current treatment algorithms. <i>Blood Cancer Journal</i> , 2020, 10, 94.	2.8	178
76	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , 2004, 104, 4188-4193.	0.6	177
77	The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. <i>Blood</i> , 2011, 118, 4663-4665.	0.6	176
78	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. <i>Blood</i> , 2005, 106, 1042-1047.	0.6	172
79	Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. <i>Kidney International</i> , 2008, 73, 1282-1288.	2.6	171
80	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	2.8	171
81	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	2.8	170
82	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 230-269.	2.3	166
83	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. <i>Mayo Clinic Proceedings</i> , 2011, 86, 12-18.	1.4	164
84	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	0.8	163
85	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1126-1137.	0.8	161
86	Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. <i>Leukemia</i> , 2011, 25, 906-908.	3.3	159
87	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. <i>Bone Marrow Transplantation</i> , 2013, 48, 557-561.	1.3	158
88	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007, 82, 323-341.	1.4	155
89	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 1317-1330.	5.1	155
90	Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. <i>Nature Communications</i> , 2018, 9, 1691.	5.8	153

#	ARTICLE	IF	CITATIONS
91	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. <i>Blood</i> , 2009, 114, 2926-2935.	0.6	152
92	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. <i>Mayo Clinic Proceedings</i> , 2010, 85, 824-833.	1.4	152
93	VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. <i>Blood</i> , 2004, 104, 2886-2892.	0.6	147
94	ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. <i>Leukemia</i> , 2007, 21, 1549-1560.	3.3	147
95	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4529-4535.	0.8	147
96	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. <i>Blood</i> , 2010, 116, 5126-5129.	0.6	146
97	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
98	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	0.6	146
99	Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. <i>Leukemia</i> , 2008, 22, 1933-1937.	3.3	144
100	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. <i>Blood</i> , 2012, 119, 5397-5404.	0.6	144
101	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. <i>Nature Communications</i> , 2018, 9, 4832.	5.8	144
102	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007, 82, 323-341.	1.4	143
103	Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1179-1184.	1.4	142
104	Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. <i>Leukemia</i> , 2014, 28, 1537-1542.	3.3	142
105	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 11-20.	2.3	142
106	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1582-1596.	5.1	141
107	Expression of VEGF and its receptors by myeloma cells. <i>Leukemia</i> , 2003, 17, 2025-2031.	3.3	140
108	Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial. <i>Clinical Cancer Research</i> , 2013, 19, 4816-4823.	3.2	140

#	ARTICLE	IF	CITATIONS
109	High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. <i>Leukemia</i> , 2013, 27, 680-685.	3.3	138
110	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029.	3.0	138
111	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1685-1717.	2.3	138
112	Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2010, 85, 905-912.	1.4	137
113	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1716-1730.	3.3	136
114	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
115	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. <i>Blood</i> , 2004, 104, 1159-1165.	0.6	134
116	Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. <i>Blood</i> , 2012, 120, 56-62.	0.6	133
117	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016, 22, 1411-1420.	15.2	133
118	Systemic amyloidosis from A (AA) to T (ATTR): a review. <i>Journal of Internal Medicine</i> , 2021, 289, 268-292.	2.7	133
119	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2009, 114, 518-521.	0.6	130
120	Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2009, 114, 785-790.	0.6	127
121	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	2.8	126
122	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. <i>American Journal of Hematology</i> , 2008, 83, 614-617.	2.0	123
123	Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2003, 78, 34-39.	1.4	122
124	Neutralizing B-Cell-Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model. <i>Clinical Cancer Research</i> , 2007, 13, 5903-5909.	3.2	122
125	Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 27, 1299-1303.	1.3	119
126	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. <i>Blood</i> , 2010, 115, 1343-1350.	0.6	119



#	ARTICLE	IF	CITATIONS
127	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood</i> , 2012, 119, 4860-4867.	0.6	119
128	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 823-829.	0.3	117
129	Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. <i>European Journal of Haematology</i> , 2008, 80, 397-406.	1.1	116
130	Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. <i>Leukemia</i> , 2002, 16, 1311-1318.	3.3	115
131	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
132	Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. <i>Haematologica</i> , 2007, 92, 1415-1418.	1.7	114
133	Progression in smoldering Waldenström macroglobulinemia: long-term results. <i>Blood</i> , 2012, 119, 4462-4466.	0.6	113
134	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1154-1165.	2.3	113
135	Discordance between serum cardiac biomarker and immunoglobulin-free light chain response in patients with immunoglobulin light chain amyloidosis treated with immune modulatory drugs. <i>American Journal of Hematology</i> , 2010, 85, 757-759.	2.0	111
136	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , 2014, 124, 907-912.	0.6	111
137	Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance. <i>Journal of Clinical Oncology</i> , 2005, 23, 5668-5674.	0.8	110
138	Thalidomide and lenalidomide in the treatment of multiple myeloma. <i>European Journal of Cancer</i> , 2006, 42, 1612-1622.	1.3	110
139	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
140	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	0.8	110
141	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. <i>Leukemia</i> , 2014, 28, 2060-2065.	3.3	109
142	Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2009, 43, 619-625.	1.3	108
143	MYC dysregulation in the progression of multiple myeloma. <i>Leukemia</i> , 2020, 34, 322-326.	3.3	108
144	Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3132-3137.	0.4	106

#	ARTICLE	IF	CITATIONS
145	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2012, 118, 1585-1592.	2.0	106
146	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	1.4	106
147	Prognostic value of angiogenesis in solitary bone plasmacytoma. <i>Blood</i> , 2003, 101, 1715-1717.	0.6	105
148	MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2007, 282, 29831-29846.	1.6	104
149	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. <i>Leukemia</i> , 2011, 25, 689-696.	3.3	104
150	Acute Superior Mesenteric Venous Thrombosis: One Disease Or Two?. <i>American Journal of Gastroenterology</i> , 2003, 98, 1299-1304.	0.2	102
151	Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. <i>Leukemia and Lymphoma</i> , 2010, 51, 2181-2187.	0.6	102
152	Immunophenotyping in multiple myeloma and related plasma cell disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 433-451.	0.7	101
153	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 871-890.	2.0	101
154	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.	0.8	100
155	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1615-1624.	2.0	99
156	Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells. <i>Advanced Materials</i> , 2007, 19, 711-716.	11.1	98
157	Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General Population. <i>Mayo Clinic Proceedings</i> , 2012, 87, 517-523.	1.4	98
158	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
159	Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. <i>Annals of Hematology</i> , 2002, 81, 312-319.	0.8	97
160	Cardiac Amyloidosis: A Practical Approach to Diagnosis and Management. <i>American Journal of Medicine</i> , 2011, 124, 1006-1015.	0.6	97
161	Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. <i>Blood Cancer Journal</i> , 2013, 3, e143-e143.	2.8	97
162	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. <i>Haematologica</i> , 2009, 94, 380-386.	1.7	94

#	ARTICLE	IF	CITATIONS
163	Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1071-1079.	1.4	94
164	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. <i>Mayo Clinic Proceedings</i> , 2015, 90, 587-596.	1.4	92
165	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. <i>Leukemia</i> , 2017, 31, 1562-1569.	3.3	92
166	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	2.8	92
167	Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. <i>Leukemia</i> , 2013, 27, 208-212.	3.3	91
168	Clinical implication of centrosome amplification in plasma cell neoplasm. <i>Blood</i> , 2006, 107, 3669-3675.	0.6	90
169	Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1131-1135.	1.4	90
170	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e296-e296.	2.8	90
171	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	0.6	90
172	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. <i>Leukemia</i> , 2004, 18, 624-627.	3.3	88
173	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2032-2036.	0.4	88
174	Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2004, 22, 2477-2488.	0.8	87
175	Impact of early relapse after auto-SCT for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2008, 42, 413-420.	1.3	87
176	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. <i>Leukemia</i> , 2016, 30, 2208-2213.	3.3	87
177	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. <i>Mayo Clinic Proceedings</i> , 2019, 94, 465-471.	1.4	87
178	An oncolytic measles virus engineered to enter cells through the CD20 antigen. <i>Molecular Therapy</i> , 2003, 7, 62-72.	3.7	86
179	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. <i>Leukemia</i> , 2012, 26, 1091-1097.	3.3	85
180	A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. <i>Leukemia</i> , 2013, 27, 220-225.	3.3	85

#	ARTICLE	IF	CITATIONS
181	Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. <i>Oncogene</i> , 2010, 29, 1190-1202.	2.6	84
182	The clinical significance of cereblon expression in multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 23-28.	0.4	84
183	Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. <i>Leukemia</i> , 2003, 17, 1865-1870.	3.3	83
184	Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. <i>Leukemia and Lymphoma</i> , 2008, 49, 36-41.	0.6	83
185	Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. <i>American Journal of Hematology</i> , 2009, 84, 799-802.	2.0	83
186	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. <i>Bone Marrow Transplantation</i> , 2004, 34, 161-167.	1.3	82
187	Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. <i>Blood Cancer Journal</i> , 2017, 7, e618-e618.	2.8	82
188	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 500-505.	1.2	81
189	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. <i>Blood Cancer Journal</i> , 2015, 5, e364-e364.	2.8	81
190	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. <i>Blood Cancer Journal</i> , 2018, 8, 123.	2.8	81
191	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
192	NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 8-19.	2.3	80
193	CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. <i>Leukemia</i> , 2005, 19, 1466-1470.	3.3	79
194	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 146, 164-170.	1.2	79
195	Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. <i>American Journal of Hematology</i> , 2011, 86, 251-255.	2.0	78
196	High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. <i>Blood</i> , 2012, 119, 1117-1122.	0.6	78
197	Transplantation for amyloidosis. <i>Current Opinion in Oncology</i> , 2007, 19, 136-141.	1.1	77
198	Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. <i>Leukemia</i> , 2010, 24, 1350-1356.	3.3	77

#	ARTICLE	IF	CITATIONS
199	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. <i>Blood</i> , 2011, 118, 1979-1988.	0.6	77
200	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. <i>Blood Cancer Journal</i> , 2021, 11, 24.	2.8	77
201	Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 87-93.	2.0	76
202	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, 181-186.	2.0	76
203	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	2.0	76
204	Many facets of bortezomib resistance/susceptibility. <i>Blood</i> , 2008, 112, 2177-2178.	0.6	75
205	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	2.0	75
206	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.. <i>Bone Marrow Transplantation</i> , 2013, 48, 1302-1307.	1.3	74
207	Outcomes of patients with POEMS syndrome treated initially with radiation. <i>Blood</i> , 2013, 122, 68-73.	0.6	74
208	Molecular signatures of multiple myeloma progression through single cell RNA-Seq. <i>Blood Cancer Journal</i> , 2019, 9, 2.	2.8	74
209	Acquired von Willebrand's syndrome: A single institution experience. <i>American Journal of Hematology</i> , 2003, 72, 243-247.	2.0	72
210	Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1964-1968.	2.2	72
211	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
212	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	3.3	72
213	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	2.0	71
214	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. <i>Clinical Cancer Research</i> , 2017, 23, 3980-3993.	3.2	71
215	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
216	Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. <i>British Journal of Haematology</i> , 2008, 141, 792-798.	1.2	70

#	ARTICLE	IF	CITATIONS
217	Smoldering multiple myeloma requiring treatment: time for a new definition?. <i>Blood</i> , 2013, 122, 4172-4181.	0.6	70
218	Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2010, 85, 232-238.	1.4	69
219	Trends and outcomes of modern staging of solitary plasmacytoma of bone. <i>American Journal of Hematology</i> , 2012, 87, 647-651.	2.0	69
220	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	3.3	69
221	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. <i>Blood Cancer Journal</i> , 2015, 5, e338-e338.	2.8	68
222	Natural history of t(11;14) multiple myeloma. <i>Leukemia</i> , 2018, 32, 131-138.	3.3	67
223	MRK003, a $\hat{\text{I}}^3$ -secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. <i>Leukemia</i> , 2012, 26, 340-348.	3.3	65
224	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.	2.0	64
225	Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. <i>Leukemia</i> , 2016, 30, 1094-1102.	3.3	64
226	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
227	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.	2.8	64
228	Targeting $\text{BCL}^2$ with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 418-427.	2.0	64
229	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. <i>Blood</i> , 2022, 139, 492-501.	0.6	64
230	Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. <i>Leukemia</i> , 2007, 21, 2043-2046.	3.3	63
231	Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. <i>Bone Marrow Transplantation</i> , 2011, 46, 970-975.	1.3	63
232	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. <i>Heart</i> , 2014, 100, 383-388.	1.2	63
233	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. <i>Leukemia</i> , 2017, 31, 130-135.	3.3	63
234	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. <i>Bone Marrow Transplantation</i> , 2004, 34, 235-239.	1.3	62

#	ARTICLE	IF	CITATIONS
235	Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1 $\beta$ levels in patients with MGUS. <i>Blood</i> , 2011, 118, 6529-6534.	0.6	62
236	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. <i>Blood Cancer Journal</i> , 2015, 5, e310-e310.	2.8	62
237	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 389-400.	2.3	62
238	New investigational drugs with single-agent activity in multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e451-e451.	2.8	62
239	Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2009, 84, 397-400.	2.0	61
240	Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1097-1101.	0.4	61
241	Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation. <i>Archives of Dermatology</i> , 2005, 141, 1277-82.	1.7	60
242	Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. <i>Leukemia</i> , 2014, 28, 398-403.	3.3	60
243	Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. <i>Leukemia</i> , 2018, 32, 986-995.	3.3	60
244	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. <i>Blood</i> , 2005, 105, 4470-4476.	0.6	59
245	Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. <i>Blood</i> , 2010, 116, 2019-2025.	0.6	59
246	Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. <i>Blood</i> , 2011, 118, 1763-1765.	0.6	59
247	Second auto-SCT for treatment of relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2013, 48, 568-573.	1.3	59
248	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
249	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
250	Thalidomide as an anti-cancer agent. <i>Journal of Cellular and Molecular Medicine</i> , 2002, 6, 160-174.	1.6	58
251	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
252	Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. <i>Leukemia Research</i> , 2007, 31, 591-598.	0.4	57

#	ARTICLE	IF	CITATIONS
253	Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 605-611.	1.3	57
254	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. <i>American Journal of Hematology</i> , 2011, 86, 640-645.	2.0	57
255	Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. <i>Bone Marrow Transplantation</i> , 2011, 46, 943-949.	1.3	57
256	Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. <i>Cancer</i> , 2012, 118, 6105-6109.	2.0	57
257	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57
258	Immune Therapies in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5453-5460.	3.2	57
259	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. <i>Leukemia</i> , 2016, 30, 633-639.	3.3	57
260	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e600-e600.	2.8	57
261	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92.	1.4	57
262	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
263	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. <i>Blood Cancer Journal</i> , 2019, 9, 102.	2.8	57
264	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. <i>Oncogene</i> , 2005, 24, 5888-5896.	2.6	56
265	R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. <i>Experimental Hematology</i> , 2008, 36, 568-576.	0.2	56
266	TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. <i>American Journal of Hematology</i> , 2010, 85, 675-686.	2.0	56
267	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e454-e454.	2.8	56
268	Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. <i>Mayo Clinic Proceedings</i> , 2010, 85, 532-537.	1.4	55
269	Gene signature combinations improve prognostic stratification of multiple myeloma patients. <i>Leukemia</i> , 2016, 30, 1071-1078.	3.3	55
270	Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway. <i>PLoS ONE</i> , 2012, 7, e50005.	1.1	55



#	ARTICLE	IF	CITATIONS
271	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	2.3	55
272	Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplantation, 2001, 28, 951-956.	1.3	54
273	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood, 2005, 106, 706-712.	0.6	54
274	Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. American Journal of Hematology, 2009, 84, 401-407.	2.0	54
275	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	0.6	54
276	PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. Leukemia and Lymphoma, 2018, 59, 2524-2534.	0.6	54
277	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 2430-2442.	0.8	53
278	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 485-490.	1.3	52
279	Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). European Journal of Haematology, 2018, 100, 215-217.	1.1	52
280	Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplantation, 2016, 51, 1449-1455.	1.3	51
281	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood, 2016, 128, 2415-2422.	0.6	51
282	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	1.3	51
283	On Appetite and Its Loss. Journal of Clinical Oncology, 2000, 18, 2930-2932.	0.8	50
284	94: Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect?. Biology of Blood and Marrow Transplantation, 2008, 14, 36-37.	2.0	50
285	Clinical course and prognosis of non-secretory multiple myeloma. European Journal of Haematology, 2015, 95, 57-64.	1.1	50
286	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	0.6	50
287	Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American Journal of Hematology, 2010, 85, 664-669.	2.0	49
288	A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. Haematologica, 2013, 98, 988-992.	1.7	49

#	ARTICLE	IF	CITATIONS
289	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
290	The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2019, 33, 2924-2933.	3.3	49
291	Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 1-2.	1.4	49
292	Bone marrow angiogenesis in multiple myeloma: effect of therapy. <i>British Journal of Haematology</i> , 2002, 119, 665-671.	1.2	48
293	Expression of CD52 on plasma cells in plasma cell proliferative disorders. <i>Blood</i> , 2003, 102, 1075-1077.	0.6	48
294	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2012, 156, 326-333.	1.2	48
295	Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. <i>Leukemia and Lymphoma</i> , 2016, 57, 2827-2832.	0.6	48
296	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	0.6	48
297	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.	2.0	47
298	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. <i>Blood Cancer Journal</i> , 2018, 8, 96.	2.8	47
299	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	2.0	47
300	The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. <i>Blood</i> , 2009, 114, 2617-2618.	0.6	45
301	Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17,315 patients. <i>Leukemia</i> , 2013, 27, 1391-1393.	3.3	45
302	Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. <i>Leukemia</i> , 2014, 28, 1519-1528.	3.3	45
303	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
304	Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. <i>Blood Cancer Journal</i> , 2016, 6, e397-e397.	2.8	45
305	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
306	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	1.2	45

#	ARTICLE	IF	CITATIONS
307	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	3.3	45
308	The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. <i>Leukemia</i> , 2019, 33, 863-883.	3.3	45
309	Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. <i>Gynecologic Oncology</i> , 2013, 130, 441-445.	0.6	44
310	Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 1616-1622.	1.3	44
311	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. <i>Leukemia</i> , 2018, 32, 729-735.	3.3	44
312	Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 43-44.	0.6	44
313	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , 2022, 9, e143-e161.	2.2	44
314	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)- $\beta$ inhibitors. <i>Oncogene</i> , 2005, 24, 3121-3129.	2.6	43
315	Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1340-1343.	0.4	43
316	Systemic Immunoglobulin Light Chain Amyloidosisâ€“Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	1.4	43
317	N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. <i>Leukemia</i> , 2020, 34, 2749-2753.	3.3	43
318	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	0.6	43
319	Extramedullary disease in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 161.	2.8	43
320	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 3748-3759.	2.5	43
321	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.	3.3	43
322	High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. <i>Bone Marrow Transplantation</i> , 2001, 28, 381-385.	1.3	42
323	Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. <i>Blood</i> , 2010, 115, 2348-2353.	0.6	42
324	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	0.9	42

#	ARTICLE	IF	CITATIONS
325	Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 28-29.	0.6	42
326	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	2.0	41
327	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
328	Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. <i>Blood</i> , 2019, 133, 652-659.	0.6	41
329	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
330	Relationship Between Depth of Response and Outcome in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4933-4937.	0.8	40
331	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. <i>Lancet Haematology</i> , 2014, 1, e28-e36.	2.2	40
332	Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1546-1553.	2.0	40
333	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
334	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.	3.3	40
335	Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 26-27.	0.6	40
336	Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2008, 83, 297-303.	1.4	39
337	Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. <i>American Journal of Hematology</i> , 2010, 85, 431-434.	2.0	39
338	Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2011, 118, 4359-4362.	0.6	39
339	Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. <i>Annals of Hematology</i> , 2011, 90, 101-106.	0.8	39
340	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e528-e528.	2.8	39
341	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2018, 32, 1567-1574.	3.3	39
342	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. <i>JCI Insight</i> , 2018, 3, .	2.3	39

#	ARTICLE	IF	CITATIONS
343	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. <i>Leukemia</i> , 2022, 36, 1066-1077.	3.3	39
344	Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation – case report and review of literature. <i>Annals of Hematology</i> , 2001, 80, 430-435.	0.8	38
345	Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 440-444.	2.2	38
346	Multiple myeloma – current issues and controversies. <i>Cancer Treatment Reviews</i> , 2010, 36, S3-S11.	3.4	38
347	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015, 90, 981-985.	2.0	38
348	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	5.8	38
349	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016, 6, e512-e512.	2.8	38
350	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.2	38
351	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
352	Immune-based therapies in the management of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 84.	2.8	38
353	Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2002, 30, 161-165.	1.3	37
354	IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenström's Macroglobulinemia (SWM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 74-76.	0.2	37
355	Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1233-1237.	2.0	37
356	Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. <i>Leukemia</i> , 2015, 29, 1195-1201.	3.3	37
357	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. <i>Cancer</i> , 2016, 122, 2197-2205.	2.0	37
358	A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e581-e581.	2.8	37
359	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.	2.0	37
360	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.	3.3	37

#	ARTICLE	IF	CITATIONS
361	High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. <i>New England Journal of Medicine</i> , 2008, 358, 91-93.	13.9	36
362	Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 222-228.	2.0	36
363	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. <i>Leukemia and Lymphoma</i> , 2015, 56, 3357-3364.	0.6	36
364	Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e363-e363.	2.8	36
365	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.	2.0	36
366	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36
367	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	2.8	36
368	Antimyeloma activity of two novel N-substituted and tetrafluorinated thalidomide analogs. <i>Leukemia</i> , 2005, 19, 1253-1261.	3.3	35
369	Proteasome $\beta^2$ Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics. <i>Clinical Cancer Research</i> , 2008, 14, 3503-3513.	3.2	35
370	Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. <i>Blood</i> , 2011, 118, 2985-2987.	0.6	35
371	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.	2.0	35
372	Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. <i>Leukemia</i> , 2010, 24, 1498-1505.	3.3	34
373	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 375-378.	2.0	34
374	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1513-1518.	1.3	34
375	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
376	Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. <i>Blood Cancer Journal</i> , 2019, 9, 72.	2.8	34
377	Response to Rituximab in Patients with Type II Cryoglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 140-144.	1.4	33
378	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33

#	ARTICLE	IF	CITATIONS
379	Early mortality in multiple myeloma. <i>Leukemia</i> , 2015, 29, 1616-1618.	3.3	33
380	Impact of MYD88 <sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
381	Reply to "Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients". <i>Leukemia</i> , 2008, 22, 1281-1282.	3.3	32
382	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014, 89, 1051-1054.	2.0	32
383	Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2014, 123, 647-649.	0.6	32
384	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. <i>Leukemia</i> , 2016, 30, 1079-1085.	3.3	32
385	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
386	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
387	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). <i>Blood</i> , 2015, 126, 727-727.	0.6	32
388	Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. <i>British Journal of Haematology</i> , 2003, 123, 305-308.	1.2	31
389	Soluble suppression of tumorigenicity 2 (sT <sub>2</sub> ), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT <sup>pro</sup> BNP and troponin T. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	2.0	31
390	E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. <i>Leukemia</i> , 2017, 31, 2642-2651.	3.3	31
391	The evolution of stem-cell transplantation in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 123-133.	1.1	31
392	Daratumumab in untreated newly diagnosed multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071989487.	1.1	31
393	Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.. <i>Blood</i> , 2006, 108, 798-798.	0.6	31
394	Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8039-8039.	0.8	31
395	Drug Insight: thalidomide as a treatment for multiple myeloma. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 262-270.	4.3	30
396	Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. <i>Neurology</i> , 2010, 74, 913-918.	1.5	30

#	ARTICLE	IF	CITATIONS
397	Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1543-1547.	1.3	30
398	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. <i>Leukemia</i> , 2013, 27, 2062-2066.	3.3	30
399	<scp>AT</scp>â€101 downregulates <scp>BCL</scp>2 and <scp>MCL</scp>1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and <scp>W</scp>aldenstrÅm macroglobulinaemia. <i>British Journal of Haematology</i> , 2014, 164, 352-365.	1.2	30
400	Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 35.	0.8	30
401	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	2.0	30
402	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e401-e401.	2.8	30
403	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Leukemia</i> , 2017, 31, 92-99.	3.3	30
404	Treating Multiple Myeloma Patients With Oral Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 243-251.	0.2	30
405	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017, 52, 1126-1132.	1.3	30
406	Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. <i>American Journal of Hematology</i> , 2017, 92, 220-221.	2.0	30
407	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017, 52, 34-40.	1.3	30
408	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). <i>Blood</i> , 2018, 132, LBA-2-LBA-2.	0.6	30
409	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. <i>PLoS Genetics</i> , 2018, 14, e1007111.	1.5	30
410	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 651-651.	0.6	30
411	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	2.8	30
412	Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 458-463.	0.2	29
413	Impact of highâ€risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. <i>British Journal of Haematology</i> , 2011, 155, 340-348.	1.2	29
414	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445.	1.7	29



#	ARTICLE	IF	CITATIONS
415	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 739-746.	1.4	29
416	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
417	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	3.3	29
418	Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. <i>Blood</i> , 2020, 136, 24-26.	0.6	29
419	Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8005-8005.	0.8	29
420	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.2	28
421	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
422	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 744-750.	2.5	28
423	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
424	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650.	2.0	28
425	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	2.8	28
426	Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1134-1140.	2.0	27
427	Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. <i>Blood Cancer Journal</i> , 2015, 5, e271-e271.	2.8	27
428	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718.	3.3	27
429	Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin. <i>Journal of Clinical Oncology</i> , 2019, 37, 171-173.	0.8	27
430	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. <i>Haematologica</i> , 2019, 104, 2061-2074.	1.7	27
431	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 103.	2.8	27
432	Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. <i>Blood</i> , 2019, 133, 763-766.	0.6	27

#	ARTICLE	IF	CITATIONS
433	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
434	Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 301-301.	0.6	27
435	A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 509-509.	0.6	27
436	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. <i>Blood</i> , 2016, 128, 488-488.	0.6	27
437	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.2	27
438	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. <i>American Journal of Hematology</i> , 2012, 87, 277-283.	2.0	26
439	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.	2.8	26
440	Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 1797-1804.	2.5	26
441	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i> , 2019, 134, 1875-1875.	0.6	26
442	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma. <i>Blood</i> , 2008, 112, 866-866.	0.6	26
443	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3138-3138.	0.6	26
444	Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA3-LBA3.	0.8	26
445	Plasma Cell Labeling Index. , 2005, 113, 25-36.		25
446	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. <i>Leukemia</i> , 2015, 29, 2033-2038.	3.3	25
447	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.	1.1	25
448	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
449	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). <i>Targeted Oncology</i> , 2017, 12, 201-209.	1.7	25
450	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25

#	ARTICLE	IF	CITATIONS
451	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
452	Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 518-524.	0.9	25
453	ARNT/HIF <sup>1</sup> links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. <i>Cancer Medicine</i> , 2018, 7, 3899-3911.	1.3	25
454	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>European Journal of Cancer</i> , 2019, 106, 89-98.	1.3	25
455	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	1.4	25
456	Daratumumab+lenalidomide+dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma. <i>American Journal of Hematology</i> , 2020, 95, 1486-1494.	2.0	25
457	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
458	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 304-304.	0.6	25
459	Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or Tj ETQq1 1 0.784314 rgBT /Over	2.0	24
460	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 447-452.	0.2	24
461	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	2.0	24
462	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
463	Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression. <i>Blood Cancer Discovery</i> , 2020, 1, 68-81.	2.6	24
464	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 41.	2.8	24
465	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. <i>Blood Cancer Journal</i> , 2021, 11, 45.	2.8	24
466	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	2.6	24
467	Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. <i>British Journal of Haematology</i> , 2003, 122, 272-274.	1.2	23
468	Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments. <i>American Journal of Hematology</i> , 2004, 77, 7-11.	2.0	23

#	ARTICLE	IF	CITATIONS
469	Solitary plasmacytoma: Is radiation therapy sufficient?. American Journal of Hematology, 2008, 83, 695-696.	2.0	23
470	Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leukemia and Lymphoma, 2014, 55, 1968-1979.	0.6	23
471	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology, 2014, 92, 485-490.	1.1	23
472	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	2.5	23
473	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	2.5	23
474	Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m <sup>2</sup> vs. twice-weekly 27 mg/m <sup>2</sup> carfilzomib (randomized A.R.R.O.W. study). Leukemia, 2019, 33, 2934-2946.	3.3	23
475	Chimeric antigen receptor T cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. American Journal of Hematology, 2022, 97, 99-118.	2.0	23
476	Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Review of Anticancer Therapy, 2005, 5, 759-766.	1.1	22
477	Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia. Clinical and Experimental Nephrology, 2008, 12, 292-295.	0.7	22
478	A Phase II study of <sup>153</sup> Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. American Journal of Hematology, 2010, 85, 409-413.	2.0	22
479	Differential Cytopathology and Kinetics of Measles Oncolysis in Two Primary B-cell Malignancies Provides Mechanistic Insights. Molecular Therapy, 2011, 19, 1034-1040.	3.7	22
480	Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S7764.	0.6	22
481	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.4	22
482	A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (<sc>MLN</sc>8237) and Bortezomib in Relapsed Multiple Myeloma. British Journal of Haematology, 2016, 174, 323-325.	1.2	22
483	Surrogate endpoints in randomised controlled trials: a reality check. Lancet, The, 2019, 394, 281-283.	6.3	22
484	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	3.3	22
485	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. Journal of Clinical Oncology, 2021, 39, 227-237.	0.8	22
486	Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies. Archives of Pathology and Laboratory Medicine, 2022, 146, 575-590.	1.2	22

#	ARTICLE	IF	CITATIONS
487	Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8509-8509.	0.8	22
488	Financial toxicity in hematological malignancies: a systematic review. Blood Cancer Journal, 2022, 12, 74.	2.8	22
489	The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nature Communications, 2022, 13, .	5.8	22
490	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 3-17.	1.4	22
491	Treatment advances in adult immune thrombocytopenic purpura. Annals of Hematology, 2003, 82, 723-737.	0.8	21
492	High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Review of Anticancer Therapy, 2006, 6, 343-360.	1.1	21
493	The significance of monoclonal gammopathy of undetermined significance. Haematologica, 2009, 94, 1641-1644.	1.7	21
494	Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood, 2013, 122, 1746-1749.	0.6	21
495	Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. Clinical Transplantation, 2014, 28, 1084-1091.	0.8	21
496	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. British Journal of Haematology, 2017, 178, 756-763.	1.2	21
497	Delineation of the timing of second-line therapy post autologous stem cell transplant in patients with AL amyloidosis. Blood, 2017, 130, 1578-1584.	0.6	21
498	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21
499	Role of imaging in multiple myeloma. American Journal of Hematology, 2020, 95, 966-977.	2.0	21
500	Implications of detecting serum monoclonal protein by MASSAfix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	1.2	21
501	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology, 2021, 96, 1131-1136.	2.0	21
502	Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica, 2006, 91, 1033-40.	1.7	21
503	Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. British Journal of Haematology, 2006, 135, 52-61.	1.2	20
504	Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Leukemia, 2006, 20, 1863-1869.	3.3	20

#	ARTICLE	IF	CITATIONS
505	Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. <i>Bone Marrow Transplantation</i> , 2008, 41, 1013-1019.	1.3	20
506	Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. <i>British Journal of Haematology</i> , 2008, 141, 205-211.	1.2	20
507	Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. <i>American Journal of Hematology</i> , 2012, 87, 51-54.	2.0	20
508	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. <i>Bone Marrow Transplantation</i> , 2014, 49, 201-205.	1.3	20
509	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , 2018, 32, 1414-1420.	3.3	20
510	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
511	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	3.3	20
512	Direct to Drug screening as a precision medicine tool in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 54.	2.8	20
513	Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. <i>Blood Advances</i> , 2020, 4, 2789-2797.	2.5	20
514	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	2.0	20
515	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 975-975.	0.6	20
516	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2236-2244.	2.5	20
517	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	0.6	20
518	Stem cell transplantation for multiple myeloma. <i>Current Opinion in Oncology</i> , 2009, 21, 162-170.	1.1	19
519	Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2013, 31, 1201-1206.	1.2	19
520	Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma. <i>Leukemia</i> , 2013, 27, 515-516.	3.3	19
521	<sc>Akt</sc> inhibitor <sc>MK</sc>2206 selectively targets <sc>CLL B</sc> cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce <sc>CLL</sc> apoptosis. <i>British Journal of Haematology</i> , 2014, 164, 146-150.	1.2	19
522	The current status of minimal residual disease assessment in myeloma. <i>Leukemia</i> , 2014, 28, 239-240.	3.3	19

#	ARTICLE	IF	CITATIONS
523	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. American Journal of Hematology, 2015, 90, 1106-1110.	2.0	19
524	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leukemia and Lymphoma, 2015, 56, 1723-1726.	0.6	19
525	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 101-108.	2.0	19
526	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted Oncology, 2017, 12, 643-654.	1.7	19
527	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 269-277.	2.0	19
528	New developments in the management of relapsed/refractory multiple myeloma &ndash; the role of ixazomib. Journal of Blood Medicine, 2017, Volume 8, 107-121.	0.7	19
529	Minimal residual disease analysis in myeloma &quot; when, why and where. Leukemia and Lymphoma, 2018, 59, 1772-1784.	0.6	19
530	Utility and prognostic value of <sup>18</sup> F- <sup>18</sup> F- <sup>18</sup> F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	2.0	19
531	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. Scientific Reports, 2020, 10, 10250.	1.6	19
532	Current approaches to management of high-risk multiple myeloma. American Journal of Hematology, 2021, 96, 854-871.	2.0	19
533	Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. Blood, 2009, 114, 127-127.	0.6	19
534	Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. American Journal of Hematology, 2012, 87, 1-4.	2.0	18
535	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology, 2015, 90, 888-891.	2.0	18
536	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1609-1618.	1.1	18
537	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 306-311.	2.0	18
538	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	2.8	18
539	A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e31.	0.2	18
540	Stem-cell transplantation in multiple myeloma: how far have we come?. Therapeutic Advances in Hematology, 2019, 10, 204062071988811.	1.1	18

#	ARTICLE	IF	CITATIONS
541	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
542	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
543	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 120.	2.8	18
544	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014, 124, 82-82.	0.6	18
545	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8006-8006.	0.8	18
546	Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 56253-56265.	0.8	18
547	The mechanisms and therapeutic targets of ferroptosis in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 965-986.	1.5	18
548	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. <i>Leukemia</i> , 2022, 36, 877-880.	3.3	18
549	Current approaches to management of newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	18
550	Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 997-999.	1.3	17
551	A novel report of <i>IGH</i> FISH and cytogenetics in POEMS syndrome. <i>American Journal of Hematology</i> , 2008, 83, 840-841.	2.0	17
552	Immunoglobulin D amyloidosis: a distinct entity. <i>Blood</i> , 2012, 119, 44-48.	0.6	17
553	Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 184-186.	0.2	17
554	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. <i>Bone Marrow Transplantation</i> , 2016, 51, 1156-1158.	1.3	17
555	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	1.2	17
556	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	2.0	17
557	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287.	2.0	17
558	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5449-5459.	2.5	17



#	ARTICLE	IF	CITATIONS
559	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	1.2	17
560	Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 926-926.	0.6	17
561	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8004-8004.	0.8	17
562	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8001-8001.	0.8	17
563	SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. <i>Bone Marrow Transplantation</i> , 2011, 46, 956-961.	1.3	16
564	Risk adapted therapy for multiple myeloma: back to basics. <i>Leukemia and Lymphoma</i> , 2014, 55, 2219-2220.	0.6	16
565	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315.	0.6	16
566	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
567	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58.	1.4	16
568	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	2.8	16
569	Cell cycle regulation and hematologic malignancies. <i>Blood Science</i> , 2019, 1, 34-43.	0.4	16
570	Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 536-546.	1.2	16
571	The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. <i>American Journal of Hematology</i> , 2021, 96, 846-853.	2.0	16
572	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	1.4	16
573	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. <i>Blood</i> , 2008, 112, 93-93.	0.6	16
574	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012, 120, 201-201.	0.6	16
575	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. <i>Blood</i> , 2015, 126, 3038-3038.	0.6	16
576	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2012, 120, 2973-2973.	0.6	16

#	ARTICLE	IF	CITATIONS
577	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 455-464.	1.4	16
578	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal, 2022, 12, .	2.8	16
579	Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Science, 2007, 98, 1035-1040.	1.7	15
580	Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. Leukemia, 2012, 26, 1119-1122.	3.3	15
581	Treatment patterns and outcomes in elderly patients with multiple myeloma. Leukemia, 2013, 27, 971-974.	3.3	15
582	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR $\epsilon$ CD) for untreated low $\epsilon$ grade non $\epsilon$ Hodgkin lymphoma requiring therapy. American Journal of Hematology, 2017, 92, 467-472.	2.0	15
583	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. Journal of Internal Medicine, 2017, 281, 611-619.	2.7	15
584	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	1.2	15
585	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology, 2018, 182, 71-77.	1.2	15
586	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	2.0	15
587	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	3.3	15
588	Free Light Chain Assay Drift: Potential for Misdiagnosis?. journal of applied laboratory medicine, The, 2020, 5, 1411-1413.	0.6	15
589	In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer & Metabolism, 2020, 8, 29.	2.4	15
590	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. American Journal of Hematology, 2020, 95, E222-E225.	2.0	15
591	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.2	15
592	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	2.0	15
593	Autologous stem cell transplantation for multiple myeloma patients aged $\geq$ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	1.3	15
594	Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Advances, 2021, 5, 1097-1101.	2.5	15

#	ARTICLE	IF	CITATIONS
595	Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 303-303.	0.6	15
596	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2960-2960.	0.6	15
597	Fabrication of Gold Nanoparticle for Potential Application in Multiple Myeloma. <i>Journal of Biomedical Nanotechnology</i> , 2008, 4, 499-507.	0.5	14
598	Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. <i>European Journal of Haematology</i> , 2013, 91, 504-513.	1.1	14
599	Initial treatment of transplant-eligible patients in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 43-53.	1.0	14
600	Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. <i>Rare Cancers and Therapy</i> , 2015, 3, 47-68.	0.2	14
601	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 889-894.	2.0	14
602	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364.	2.0	14
603	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	2.0	14
604	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9.	2.0	14
605	Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). <i>Leukemia</i> , 2021, 35, 1797-1802.	3.3	14
606	The Prognostic Role of <i>MYC</i> Structural Variants Identified by NGS and FISH in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 5430-5439.	3.2	14
607	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. <i>Blood</i> , 2010, 116, 621-621.	0.6	14
608	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase II/III trial. <i>Blood Cancer Journal</i> , 2022, 12, 9.	2.8	14
609	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. <i>Blood Advances</i> , 2022, 6, 1232-1242.	2.5	14
610	Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. <i>British Journal of Haematology</i> , 2022, 199, 95-99.	1.2	14
611	Hypercalcemia Complicating Leukemic Transformation of Agnogenic Myeloid Metaplasia-Myelofibrosis. <i>Mayo Clinic Proceedings</i> , 1999, 74, 1233-1237.	1.4	13
612	Agnogenic myeloid metaplasia associated with Klinefelter syndrome: a case report. <i>Annals of Hematology</i> , 2002, 81, 215-218.	0.8	13

#	ARTICLE	IF	CITATIONS
613	Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. <i>Leukemia Research</i> , 2014, 38, 1358-1366.	0.4	13
614	Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016, 30, 995-998.	3.3	13
615	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1372-1377.	1.3	13
616	Pomalidomide+dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. <i>Leukemia</i> , 2018, 32, 719-728.	3.3	13
617	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E117-E120.	2.0	13
618	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 87.	2.8	13
619	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.	2.6	13
620	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 330-337.	2.0	13
621	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	0.6	13
622	Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. <i>American Journal of Hematology</i> , 2021, 96, 690-697.	2.0	13
623	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.	2.5	13
624	A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients.. <i>Blood</i> , 2009, 114, 3854-3854.	0.6	13
625	A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS8554-TPS8554.	0.8	13
626	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2763-2772.	2.5	13
627	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. <i>Blood Cancer Journal</i> , 2022, 12, 67.	2.8	13
628	Increased prevalence of light chain monoclonal gammopathy of undetermined significance (<scp>LC</scp>+<scp>MGUS</scp>) in first-degree relatives of individuals with multiple myeloma. <i>British Journal of Haematology</i> , 2012, 157, 472-475.	1.2	12
629	Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. <i>Cancer</i> , 2013, 119, 4308-4315.	2.0	12
630	The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. <i>Leukemia</i> , 2018, 32, 1243-1246.	3.3	12

#	ARTICLE	IF	CITATIONS
631	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 254-260.	1.2	12
632	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.	3.3	12
633	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	2.8	12
634	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
635	Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. <i>British Journal of Haematology</i> , 2020, 190, 249-261.	1.2	12
636	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. <i>American Journal of Hematology</i> , 2021, 96, E157-E162.	2.0	12
637	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 377-387.	1.4	12
638	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
639	Decoding DNA methylation in epigenetics of multiple myeloma. <i>Blood Reviews</i> , 2022, 51, 100872.	2.8	12
640	Frontline treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019. <i>Cancer Medicine</i> , 2021, 10, 5866-5877.	1.3	12
641	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
642	A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 332-332.	0.6	12
643	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013, 122, 407-407.	0.6	12
644	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2022, 36, 873-876.	3.3	12
645	Review: extramedullary disease in multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 802-4.	0.3	12
646	Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 104-112.	1.2	11
647	Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2012, 89, 228-235.	1.1	11
648	Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 15-21.	0.3	11

#	ARTICLE	IF	CITATIONS
649	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	2.0	11
650	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
651	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 163-171.	0.6	11
652	Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. <i>Annals of Oncology</i> , 2019, 30, 1647-1652.	0.6	11
653	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. <i>Blood Cancer Journal</i> , 2019, 9, 49.	2.8	11
654	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.	1.1	11
655	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	2.0	11
656	Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. <i>Cancer Cell International</i> , 2020, 20, 403.	1.8	11
657	Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 679-684.	1.2	11
658	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 63.	2.8	11
659	Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. <i>Blood</i> , 2012, 120, 194-194.	0.6	11
660	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results. <i>Blood</i> , 2015, 126, 4219-4219.	0.6	11
661	Cell Trafficking in Multiple Myeloma. <i>Open Journal of Hematology</i> , 2012, 3, 1.	0.4	11
662	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. <i>Blood Advances</i> , 2022, , .	2.5	11
663	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
664	Cutaneous manifestations of monoclonal gammopathy. <i>Blood Cancer Journal</i> , 2022, 12, 58.	2.8	11
665	Cutaneous and systemic amyloidoses. <i>International Journal of Dermatology</i> , 2002, 41, 133-134.	0.5	10
666	Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). <i>Bone Marrow Transplantation</i> , 2007, 40, 989-993.	1.3	10

#	ARTICLE	IF	CITATIONS
667	Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplantation, 2008, 42, 259-264.	1.3	10
668	Treatment of newly diagnosed multiple myeloma: advances in current therapy. Medical Oncology, 2010, 27, 14-24.	1.2	10
669	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2010, 148, 853-858.	1.2	10
670	A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2010, 16, S197-S198.	2.0	10
671	Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia, 2012, 26, 839-841.	3.3	10
672	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 349-357.e2.	0.2	10
673	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-analysis. European Journal of Haematology, 2017, 98, 563-568.	1.1	10
674	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	1.2	10
675	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	1.7	10
676	Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. Leukemia and Lymphoma, 2018, 59, 288-299.	0.6	10
677	Management of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 624-627.	2.3	10
678	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer Journal, 2019, 9, 20.	2.8	10
679	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.	2.0	10
680	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer Journal, 2021, 11, 26.	2.8	10
681	Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Review of Hematology, 2021, 14, 1099-1114.	1.0	10
682	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	0.6	10
683	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. Blood, 2018, 132, 2015-2015.	0.6	10
684	Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy, 2022, 39, 1976-1992.	1.3	10

#	ARTICLE	IF	CITATIONS
685	Prophylaxis of graft-versus-host disease with cyclosporine&#x2013;prednisone is associated with increased risk of chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2001, 27, 1133-1140.	1.3	9
686	Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 101-108.	0.5	9
687	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	1.7	9
688	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.	1.3	9
689	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
690	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.	1.3	9
691	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.	2.0	9
692	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	1.3	9
693	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. <i>Leukemia</i> , 2019, 33, 499-507.	3.3	9
694	Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1009-1026.	0.9	9
695	In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 78.	2.8	9
696	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. <i>Blood</i> , 2021, 137, 513-523.	0.6	9
697	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021, 5, 1029-1036.	2.5	9
698	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)&#x2013;Associated Lesions: A Case Series. <i>American Journal of Kidney Diseases</i> , 2022, 79, 202-216.	2.1	9
699	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.2	9
700	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021, 11, 158.	2.8	9
701	Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity. <i>Blood</i> , 2012, 120, 76-76.	0.6	9
702	Early Mortality in Multiple Myeloma: Risk Factors and Impact on Population Outcomes. <i>Blood</i> , 2014, 124, 1320-1320.	0.6	9



#	ARTICLE	IF	CITATIONS
703	Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study.. Journal of Clinical Oncology, 2012, 30, 8095-8095.	0.8	9
704	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	0.6	9
705	Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist, 2022, 27, e589-e596.	1.9	9
706	Dexamethasone and the risk for adrenal suppression in multiple myeloma. Leukemia, 2009, 23, 1009-1011.	3.3	8
707	Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. European Journal of Haematology, 2010, 85, 200-208.	1.1	8
708	Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. Leukemia, 2011, 25, 1195-1197.	3.3	8
709	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e569-e569.	2.8	8
710	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	3.3	8
711	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 155-161.	1.3	8
712	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
713	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.2	8
714	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. British Journal of Haematology, 2020, 191, 442-452.	1.2	8
715	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	1.3	8
716	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	2.8	8
717	BiTEing the Tumor. Journal of Clinical Oncology, 2020, 38, 2077-2079.	0.8	8
718	câ€MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomideâ€dexamethasone in myeloma. European Journal of Haematology, 2020, 105, 35-46.	1.1	8
719	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 2020, 4, 322-326.	2.5	8
720	Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. Blood Advances, 2021, 5, 367-376.	2.5	8

#	ARTICLE	IF	CITATIONS
721	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.	3.3	8
722	Post-Transplant Maintenance Treatment Options in Multiple Myeloma. <i>Oncology and Therapy</i> , 2021, 9, 69-88.	1.0	8
723	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	3.3	8
724	Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. <i>Cancer</i> , 2021, 127, 4233-4239.	2.0	8
725	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	2.0	8
726	Phase II Trial of Lenalidomide (Revlimid <sup>®</sup> ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma. <i>Blood</i> , 2008, 112, 91-91.	0.6	8
727	A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis.. <i>Blood</i> , 2009, 114, 3853-3853.	0.6	8
728	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	0.6	8
729	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. <i>Blood</i> , 2016, 128, 197-197.	0.6	8
730	A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics. <i>Blood</i> , 2016, 128, 3316-3316.	0.6	8
731	Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 3327-3327.	0.6	8
732	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7559-7559.	0.8	8
733	The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. <i>Blood</i> , 2011, 118, 2868-2868.	0.6	8
734	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.	2.8	8
735	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio $\geq 100$ . <i>Leukemia</i> , 2022, 36, 1429-1431.	3.3	8
736	A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytanadione (vitamin K1). <i>Bone Marrow Transplantation</i> , 2001, 28, 1176-1177.	1.3	7
737	Progress in the treatment of multiple myeloma. <i>Lancet, The</i> , 2006, 367, 791-792.	6.3	7
738	Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cell Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1395-1398.	2.0	7

#	ARTICLE	IF	CITATIONS
739	Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S147.	0.2	7
740	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 356-369.	0.2	7
741	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 145-167.	0.2	7
742	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447.	1.3	7
743	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019, 3, 1226-1229.	2.5	7
744	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	2.0	7
745	Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma. <i>PET Clinics</i> , 2019, 14, 391-403.	1.5	7
746	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	3.3	7
747	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.	1.3	7
748	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 944-954.	1.4	7
749	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. <i>Blood Advances</i> , 2021, 5, 2101-2105.	2.5	7
750	Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma. <i>Blood</i> , 2007, 110, 190-190.	0.6	7
751	Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? : A CIBMTR Analysis From 1989 to 2005. <i>Blood</i> , 2009, 114, 54-54.	0.6	7
752	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012, 120, 3972-3972.	0.6	7
753	Kidney Transplant Outcomes of Patients With Multiple Myeloma. <i>Kidney International Reports</i> , 2022, 7, 752-762.	0.4	7
754	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. <i>Leukemia</i> , 2022, 36, 1426-1428.	3.3	7
755	Outcomes after biochemical or clinical progression in patients with multiple myeloma. <i>Blood Advances</i> , 2023, 7, 909-917.	2.5	7
756	Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2003, 32, 1065-1069.	1.3	6

#	ARTICLE	IF	CITATIONS
757	In Vivo and in Silico studies on single versus multiple transplants for multiple myeloma. <i>Cancer Science</i> , 2007, 98, 734-739.	1.7	6
758	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 781-787.	0.6	6
759	Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. <i>Bone Marrow Transplantation</i> , 2011, 46, 291-293.	1.3	6
760	Candidate genes of Waldenström's macroglobulinemia: current evidence and research. <i>The Application of Clinical Genetics</i> , 2013, 6, 33.	1.4	6
761	Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. <i>Leukemia</i> , 2014, 28, 455-457.	3.3	6
762	Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. <i>European Journal of Haematology</i> , 2015, , n/a-n/a.	1.1	6
763	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 0, , .	3.3	6
764	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.	0.6	6
765	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. <i>Blood</i> , 2018, 132, 3233-3233.	0.6	6
766	High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels.. <i>Blood</i> , 2006, 108, 3514-3514.	0.6	6
767	Normalization of the Serum Free Light Chain (FLC) Ratio Is Associated with Superior Overall Survival among Myeloma Patients Achieving Immunofixation Negative State: Results Support Incorporation of Serum FLC Ratio in Stringent CR Definition.. <i>Blood</i> , 2008, 112, 1692-1692.	0.6	6
768	Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.. <i>Blood</i> , 2009, 114, 615-615.	0.6	6
769	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	0.6	6
770	Using Continuing Medical Education to Promote Shared Decision-Making in Patients Diagnosed with Multiple Myeloma. <i>Blood</i> , 2016, 128, 2388-2388.	0.6	6
771	Epigallocatechin-3-Gallate (EGCG), a Polyphenol Extracted from Green Tea, Has Significant In Vitro Activity Against Myeloma Cells.. <i>Blood</i> , 2006, 108, 3465-3465.	0.6	6
772	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	2.0	6
773	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 803-809.	1.3	6
774	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6

#	ARTICLE	IF	CITATIONS
775	Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma. American Journal of Hematology, 2022, , .	2.0	6
776	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€“2. Mayo Clinic Proceedings, 2010, 85, 197-199.	1.4	5
777	A Cost Effective Analysis of a Risk-Adapted Algorithm for Plerixafor Use in Autologous Peripheral Blood Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2011, 17, S159-S160.	2.0	5
778	Mobilization and Transplantation Patterns of Autologous Hematopoietic Stem Cells in Multiple Myeloma and Non-Hodgkin Lymphoma. Cancer Control, 2015, 22, 87-94.	0.7	5
779	Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Blood Cancer Journal, 2015, 5, e294-e294.	2.8	5
780	Outcome of very young (â‰¥40 years) patients with immunoglobulin light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 50-51.	1.4	5
781	New Treatment Options for the Management of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 709-712.	2.3	5
782	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	2.0	5
783	Checking in: T cells against multiple myeloma. Blood, 2017, 130, 1175-1176.	0.6	5
784	Timing of treatment of smoldering myeloma: delay until progression. Blood Advances, 2018, 2, 3050-3053.	2.5	5
785	Precision medicine in multiple myeloma: are we there yet?. Expert Review of Precision Medicine and Drug Development, 2019, 4, 51-53.	0.4	5
786	Targeted Management Strategies in Multiple Myeloma. Cancer Journal (Sudbury, Mass ), 2019, 25, 59-64.	1.0	5
787	Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. Lancet Haematology,the, 2020, 7, e704-e706.	2.2	5
788	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	1.3	5
789	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. Leukemia and Lymphoma, 2020, 61, 1752-1755.	0.6	5
790	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	1.3	5
791	Initial Therapeutic Approaches to Patients with Multiple Myeloma. Advances in Therapy, 2021, 38, 3694-3711.	1.3	5
792	Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 3087-3097.	0.6	5

#	ARTICLE	IF	CITATIONS
793	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2010, 116, 1964-1964.	0.6	5
794	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	0.6	5
795	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	0.6	5
796	High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 8586-8586.	0.8	5
797	Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8576-8576.	0.8	5
798	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8002-8002.	0.8	5
799	NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2023-2023.	0.8	5
800	Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6594-6594.	0.8	5
801	Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020, 2, 133.	0.7	5
802	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. <i>Blood</i> , 2010, 116, 2253-2253.	0.6	5
803	Characteristics and risk factors for thrombosis in <sc>POEMS</sc> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.	2.0	5
804	Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. <i>EClinicalMedicine</i> , 2021, 42, 101225.	3.2	5
805	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .	2.0	5
806	secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. <i>Blood Cancer Journal</i> , 2022, 12, 39.	2.8	5
807	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3991-3995.	2.5	5
808	Meta-analysis of ciltacabtagene autoleucl versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. <i>Current Medical Research and Opinion</i> , 2022, 38, 1759-1767.	0.9	5
809	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. <i>British Journal of Haematology</i> , 2006, 132, 698-704.	1.2	4
810	Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 415-429.	0.2	4

#	ARTICLE	IF	CITATIONS
811	Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 137-138.	1.4	4
812	Will the real myeloma please stand up?. <i>Leukemia</i> , 2013, 27, 760-761.	3.3	4
813	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. <i>American Journal of Hematology</i> , 2014, 89, 302-305.	2.0	4
814	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	1.4	4
815	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	1.3	4
816	The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?. <i>Haematologica</i> , 2019, 104, 222-225.	1.7	4
817	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	0.6	4
818	Recycling therapies for myeloma: The need for prospective trials. <i>Cancer</i> , 2019, 125, 2920-2922.	2.0	4
819	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.	2.0	4
820	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.	2.0	4
821	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. <i>Blood Cancer Journal</i> , 2020, 10, 39.	2.8	4
822	Cost-effectiveness of once weekly carfilzomib 70 mg/m <sup>2</sup> plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States. <i>Expert Review of Hematology</i> , 2020, 13, 687-696.	1.0	4
823	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021, 106, 354-361.	1.1	4
824	Case series: MRD negativity assessment using <sup>11</sup> C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 2040620721110303.	1.1	4
825	The Lysine-Specific Demethylase KDM4A/JMJD2A Acts As a Tumor Suppressor in Multiple Myeloma. <i>Blood</i> , 2018, 132, 191-191.	0.6	4
826	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37.	0.6	4
827	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.	0.6	4
828	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. <i>Blood</i> , 2010, 116, 370-370.	0.6	4

#	ARTICLE	IF	CITATIONS
829	PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma. <i>Blood</i> , 2014, 124, 3382-3382.	0.6	4
830	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
831	NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2018-2018.	0.8	4
832	A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2010, 28, 8131-8131.	0.8	4
833	Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8058-8058.	0.8	4
834	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	1.3	4
835	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017, 130, 902-902.	0.6	4
836	Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3160-3160.	0.6	4
837	Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2022, 12, 53.	2.8	4
838	Role of allogeneic stem cell transplantation in multiple myeloma. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 99-106.	1.2	3
839	Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. <i>Cancer</i> , 2010, 116, 640-646.	2.0	3
840	Digging Deeper with Allogeneic Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 335-336.	2.0	3
841	Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S156.	2.0	3
842	Blind men and an elephant. <i>Blood</i> , 2015, 125, 745-747.	0.6	3
843	Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS syndrome): a paraneoplastic syndrome. <i>Oxford Medical Case Reports</i> , 2015, 2015, 237-240.	0.2	3
844	Reply to Castillo et al.. <i>American Journal of Hematology</i> , 2018, 93, E71-E73.	2.0	3
845	Serum free light chain measurements to reduce 24h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	2.0	3
846	Time Horizons in Cost Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 582.	3.8	3



#	ARTICLE	IF	CITATIONS
847	Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.	1.3	3
848	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 95.	2.8	3
849	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. <i>British Journal of Haematology</i> , 2020, 190, 79-83.	1.2	3
850	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021, 106, 433-436.	1.1	3
851	3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. <i>Hematology</i> , 2021, 26, 652-655.	0.7	3
852	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	0.6	3
853	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. <i>Blood</i> , 2008, 112, 95-95.	0.6	3
854	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. <i>Blood</i> , 2013, 122, 2136-2136.	0.6	3
855	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3177-3177.	0.6	3
856	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015, 126, 4201-4201.	0.6	3
857	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 243-243.	0.6	3
858	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3317-3317.	0.6	3
859	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8004-8004.	0.8	3
860	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. <i>Oncotarget</i> , 2018, 9, 34582-34594.	0.8	3
861	High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy. <i>Clinical Nephrology</i> , 2018, 89, 291-299.	0.4	3
862	Abstract 5669: Mechanisms of activity and drug resistance with proteasome inhibitors in multiple myeloma: Comparison of bortezomib and the investigational drug MLN9708. , 2012, , .		3
863	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. <i>Leukemia</i> , 2022, 36, 1058-1065.	3.3	3
864	Carfilzomib 56 mg/m <sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVD): a matching-adjusted indirect treatment comparison. <i>Leukemia and Lymphoma</i> , 2022, 63, 1887-1896.	0.6	3

#	ARTICLE	IF	CITATIONS
865	The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210820.	1.1	3
866	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2022, 12, 59.	2.8	3
867	Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
868	Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. <i>Blood Advances</i> , 2022, 6, 5429-5435.	2.5	3
869	Hazards of Quality-of-Life Data for Clinical Decision Making. <i>Journal of Clinical Oncology</i> , 2001, 19, 594-595.	0.8	2
870	Autologous stem cell transplantation in the elderly including pre- and post-treatment options. <i>Bone Marrow Transplantation</i> , 2007, 40, 1115-1121.	1.3	2
871	Cardiomyopathy Following High Dose Melphalan Conditioning Prior to Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma and Primary Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S203.	2.0	2
872	Outcome assessment following treatment of isolated lymphatic recurrences in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2011, 120, S91.	0.6	2
873	Bortezomib for myeloma: optimizing treatment strategies. <i>Community Oncology</i> , 2012, 9, 272-273.	0.2	2
874	35-Year-Old Man With Fever and Abdominal Pain. <i>Mayo Clinic Proceedings</i> , 2013, 88, 866-870.	1.4	2
875	Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients. <i>Leukemia Research</i> , 2013, 37, 1527-1531.	0.4	2
876	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S130-S131.	2.0	2
877	Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. <i>European Journal of Haematology</i> , 2013, 91, 193-195.	1.1	2
878	Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 7-11.	1.0	2
879	Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'. <i>Leukemia</i> , 2018, 32, 2083-2085.	3.3	2
880	Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e115-e116.	0.2	2
881	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
882	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	0.6	2

#	ARTICLE	IF	CITATIONS
883	Paving the way to precision medicine in multiple myeloma. Expert Review of Hematology, 2021, 14, 323-327.	1.0	2
884	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes and Cancer, 2021, 60, 678-686.	1.5	2
885	Multiple Myeloma: From Baby Steps to Giant Strides. JCO Oncology Practice, 2021, 17, 419-420.	1.4	2
886	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	0.6	2
887	Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025. Clinical Cancer Research, 2022, 28, 23-26.	3.2	2
888	Plasmacytoma—Current Approach to Diagnosis and Management. , 2017, , 17-39.		2
889	Abstract 2653: Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma. Cancer Research, 2015, 75, 2653-2653.	0.4	2
890	Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma.. Blood, 2007, 110, 1487-1487.	0.6	2
891	Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2008, 112, 3467-3467.	0.6	2
892	Non-Clonal Serum Immunoglobulin Free Light Chains (FLC) as Markers of Overall Survival. Blood, 2010, 116, 3893-3893.	0.6	2
893	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Blood, 2011, 118, 2942-2942.	0.6	2
894	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	0.6	2
895	Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing. Blood, 2014, 124, 169-169.	0.6	2
896	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	0.6	2
897	Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma. Blood, 2016, 128, 4517-4517.	0.6	2
898	Outcome after second stem cell transplantation for relapsed multiple myeloma. Journal of Clinical Oncology, 2007, 25, 8118-8118.	0.8	2
899	A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination with bortezomib in patients with advanced malignancy. Journal of Clinical Oncology, 2008, 26, 2569-2569.	0.8	2
900	A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis.. Journal of Clinical Oncology, 2010, 28, 8025-8025.	0.8	2

#	ARTICLE	IF	CITATIONS
901	Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745.. Journal of Clinical Oncology, 2011, 29, 4116-4116.	0.8	2
902	Nivolumab in combination with daratumumab, with or without pomalidomide and dexamethasone, for relapsed/refractory multiple myeloma: 2 cohorts of the phase 1 CheckMate 039 safety study.. Journal of Clinical Oncology, 2017, 35, TPS3102-TPS3102.	0.8	2
903	Daratumumab-based therapies in patients with AL amyloidosis.. Journal of Clinical Oncology, 2018, 36, 8053-8053.	0.8	2
904	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	0.6	2
905	Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2021, 138, 2735-2735.	0.6	2
906	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation, 2022, 57, 295-298.	1.3	2
907	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	2.0	2
908	Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. Oncology, 2011, 25 Suppl 2, 32-43.	0.4	2
909	Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method. Blood Advances, 2022, 6, 3746-3750.	2.5	2
910	Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. Oncology and Therapy, 2022, 10, 105-122.	1.0	2
911	Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. Blood Cancer Journal, 2022, 12, 60.	2.8	2
912	Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. Frontiers in Oncology, 2022, 12, 859455.	1.3	2
913	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2022, 63, 2422-2427.	0.6	2
914	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	2
915	Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 43.	2.0	1
916	Peripheral Blood CD34 Count Can Predict Successful Progenitor Cell Mobilization in Poor Mobilizers Treated With Plerixafor and G-CSF. Biology of Blood and Marrow Transplantation, 2009, 15, 70.	2.0	1
917	Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma. Clinical Lymphoma and Myeloma, 2009, 9, S46-S47.	1.4	1
918	100 Long Term Outcome of Renal Failure in Multiple Myeloma Following Autologous Stem Cell Transplant. American Journal of Kidney Diseases, 2011, 57, B41.	2.1	1

#	ARTICLE	IF	CITATIONS
919	Reply to S. Girnius et al. Journal of Clinical Oncology, 2013, 31, 2750-2751.	0.8	1
920	Bisphosphonates in multiple myeloma: a fractured consensus. Leukemia and Lymphoma, 2015, 56, 553-554.	0.6	1
921	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 44-45.	1.4	1
922	Outcomes of Autologous Hematopoietic Stem Cell Transplant in Sporadic Late Onset NemaLine Myopathy with Associated Monoclonal Gammopathy of Unknown Significance. Biology of Blood and Marrow Transplantation, 2018, 24, S124-S125.	2.0	1
923	Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S240.	0.2	1
924	Frequent methylation of the tumor suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e159.	0.2	1
925	The adverse double-hit effect of combining cytogenetic abnormalities and ISS stage III on the outcome of patients with newly-diagnosed multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e68.	0.2	1
926	Blood mass spectrometry Detects Residual Disease Better than Standard Techniques in Immunoglobulin light chain amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e313.	0.2	1
927	Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 A.R.R.O.W. study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e31-e32.	0.2	1
928	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. HemaSphere, 2019, 3, 616.	1.2	1
929	Venetoclax For The Treatment of Translocation AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e332.	0.2	1
930	Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e5-e6.	0.2	1
931	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ~graft versus host~™-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	1.3	1
932	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	1.3	1
933	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 309.e1-309.e5.	0.6	1
934	Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e48-e51.	0.2	1
935	Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. Blood, 2018, 132, 1879-1879.	0.6	1
936	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. Blood, 2018, 132, 3303-3303.	0.6	1

#	ARTICLE	IF	CITATIONS
937	Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma. Blood, 2018, 132, 3541-3541.	0.6	1
938	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	0.6	1
939	Baseline Serum Albumin and Proteinuria Predict Renal Response after Autologous Stem Cell Transplantation in AL Amyloidosis.. Blood, 2005, 106, 1166-1166.	0.6	1
940	Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect?.. Blood, 2007, 110, 939-939.	0.6	1
941	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. Blood, 2009, 114, 956-956.	0.6	1
942	Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. Blood, 2010, 116, 1893-1893.	0.6	1
943	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). Blood, 2010, 116, 3053-3053.	0.6	1
944	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. Blood, 2010, 116, 863-863.	0.6	1
945	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	0.6	1
946	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. Blood, 2011, 118, 2950-2950.	0.6	1
947	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). Blood, 2012, 120, 602-602.	0.6	1
948	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. Blood, 2012, 120, 946-946.	0.6	1
949	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	0.6	1
950	Measurement of the Proliferation of Clonal Plasma Cells By Multiparametric Flow Cytometry Is a Clinically Useful Tool in Multiple Myeloma. Blood, 2014, 124, 2053-2053.	0.6	1
951	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	0.6	1
952	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	0.6	1
953	Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base. Blood, 2016, 128, 3249-3249.	0.6	1
954	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	0.6	1

#	ARTICLE	IF	CITATIONS
955	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	0.6	1
956	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	0.6	1
957	Correlation of bone marrow angiogenesis and response to thalidomide dexamethasone in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2006, 24, 7621-7621.	0.8	1
958	Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.. <i>Journal of Clinical Oncology</i> , 2010, 28, 8125-8125.	0.8	1
959	Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8608-8608.	0.8	1
960	Outcomes of young patients with Waldenstrom macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8609-8609.	0.8	1
961	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8038-8038.	0.8	1
962	Factors predicting organ response in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8048-8048.	0.8	1
963	Combination of the mTOR Inhibitor Rapamycin and Revmimidâ,¢ (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 1492-1492.	0.6	1
964	Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies.. <i>Blood</i> , 2004, 104, 2354-2354.	0.6	1
965	Phenotypic Characterization of the CD45+ and CD45â~ Plasma Cell Compartments in Monoclonal Gammopathies.. <i>Blood</i> , 2006, 108, 3505-3505.	0.6	1
966	Effect of Thrombotic Events on Overall Survival in Patients with Newly Diagnosed Myeloma: Analysis from a Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00).. <i>Blood</i> , 2007, 110, 2734-2734.	0.6	1
967	Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines. <i>Blood</i> , 2010, 116, 3014-3014.	0.6	1
968	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. <i>Blood</i> , 2011, 118, 2945-2945.	0.6	1
969	Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma. <i>Blood</i> , 2014, 124, 2059-2059.	0.6	1
970	Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 1839-1839.	0.6	1
971	Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 2105-2105.	0.6	1
972	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment na~ve (TN) Waldenstr~m macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7552-7552.	0.8	1

#	ARTICLE	IF	CITATIONS
973	Natural history of t(11;14) multiple myeloma (MM).. Journal of Clinical Oncology, 2017, 35, 8014-8014.	0.8	1
974	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	0.6	1
975	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	0.6	1
976	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	0.6	1
977	Should we measure clonal circulating plasma cells in light chain amyloidosis?. Oncotarget, 2018, 9, 35607-35608.	0.8	1
978	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	0.6	1
979	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	0.6	1
980	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. Blood, 2018, 132, 719-719.	0.6	1
981	Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. study.. Journal of Clinical Oncology, 2019, 37, 8027-8027.	0.8	1
982	Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).. Journal of Clinical Oncology, 2020, 38, e19112-e19112.	0.8	1
983	Natural history of acute portal and acute mesenteric venous thrombosis. Gastroenterology, 2000, 118, A972.	0.6	0
984	59-Year-Old Man With Pelvic Pain and Hypergammaglobulinemia. Mayo Clinic Proceedings, 2001, 76, 311-314.	1.4	0
985	Autologous stem cell transplantation for multiple myeloma in patients over 70 years: A matched comparison with patients under 65 years. Biology of Blood and Marrow Transplantation, 2006, 12, 114.	2.0	0
986	Ursodiol prophylaxis against hepatic veno-occlusive disease in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Biology of Blood and Marrow Transplantation, 2006, 12, 137-138.	2.0	0
987	102: Implications of body weight calculations for autologous peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 40.	2.0	0
988	Role of autologous stem cell transplantation in multiple myeloma. Current Hematologic Malignancy Reports, 2007, 2, 121-127.	1.2	0
989	88: Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceding Plasma Cell Disorders. Biology of Blood and Marrow Transplantation, 2008, 14, 35.	2.0	0
990	255: Rescue Mobilization of Hematopoietic Progenitor Cells with AMD3100 + G-CSF is Successful in Patients Who Previously Failed Mobilization. Biology of Blood and Marrow Transplantation, 2008, 14, 94.	2.0	0



#	ARTICLE	IF	CITATIONS
991	Stem Cell Mobilization In Patients With Newly Diagnosed Multiple Myeloma Following Therapy With Lenalidomide and Dexamethasone. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 66.	2.0	0
992	Continued M Protein Responses Beyond Day 100 After Autologous Transplantation for Myeloma: Implications for Post Transplant Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 70-71.	2.0	0
993	Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1033-1035.	0.6	0
994	Antiangiogenic Agents in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S44-S45.	1.4	0
995	ASH 2009 meeting reportâ€”Top 10 clinically oriented abstracts in multiple myeloma. <i>American Journal of Hematology</i> , 2010, 85, 210-213.	2.0	0
996	Predictors for â€œPoor Mobilizersâ€•After Cyclophosphamide Mobilization in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S202-S203.	2.0	0
997	Risk factors for thromboembolism within the first 30days of endometrial cancer surgery. <i>Gynecologic Oncology</i> , 2011, 120, S93.	0.6	0
998	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S247.	2.0	0
999	Carfilzomib for myeloma: proteasome inhibition with a different flavor?. <i>Community Oncology</i> , 2012, 9, 270-271.	0.2	0
1000	Redefining Engraftment Syndrome: The New Mayo Clinic Criteria. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S180-S181.	2.0	0
1001	Post-transplant therapy in multiple myeloma: a hung jury?. <i>Lancet Haematology,the</i> , 2014, 1, e90-e91.	2.2	0
1002	Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S238.	0.2	0
1003	Measurement of the proliferation of clonal plasma cells by multiparametric flow cytometry is a clinically useful tool in relapsed multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S238-S239.	0.2	0
1004	Predictors of Survival in Multiple Myeloma Patients after Relapse from a Delayed Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S137.	2.0	0
1005	Updated Results of the Mayo Clinic Risk Adapted Algorithm for Peripheral Blood Stem Cell Mobilization Utilizing G-CSF and Plerixafor. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S50-S51.	2.0	0
1006	A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S225-S226.	0.2	0
1007	The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S239.	0.2	0
1008	Timing of Stem Cell Transplantation and Outcomes in Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S64-S65.	2.0	0

#	ARTICLE	IF	CITATIONS
1009	Impact of Day-100 Response Post Autologous Stem Cell Transplantation (ASCT) in Waldenström Macroglobulinemia (WM). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S130.	2.0	0
1010	Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 153-158.	0.3	0
1011	A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e16.	0.2	0
1012	Identifying the Right Patient for Bcl2 Inhibition in Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S144-S145.	0.2	0
1013	Characterization of Long-Term Multiple Myeloma Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S252-S253.	2.0	0
1014	Monoclonal Antibodies for Myeloma: Make It Easy!. <i>Journal of Oncology Practice</i> , 2018, 14, 423-424.	2.5	0
1015	Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S248-S249.	0.2	0
1016	Outcomes with different administration schedules of VRD as first-line therapy in multiple myeloma: a retrospective analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e203.	0.2	0
1017	Safety and Efficacy of Once-Weekly Carfilzomib (K) Dosing in Frail Patients (pts): A Subgroup Analysis from the Phase 3 A.R.R.O.W. Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S320-S321.	0.2	0
1018	Venetoclax for the Treatment of Multiple Myeloma: Outcomes Outside of Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e278-e279.	0.2	0
1019	Serum BCMA Levels Predict Outcomes for Patients with MGUS and Smoldering Multiple Myeloma (SMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e312.	0.2	0
1020	Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e225-e226.	0.2	0
1021	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e305.	0.2	0
1022	Mass cytometry identifies expansion of double positive and PD-1+ T cell subsets in the tumor microenvironment of patients with POEMS syndrome.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e322.	0.2	0
1023	Impact of Minimal Residual Negativity on Outcomes in Light Chain Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e331-e332.	0.2	0
1024	The role of bone marrow biopsy in patients with plasma cell disorders; should all patients with a monoclonal protein be biopsied?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e333.	0.2	0
1025	Detection and Prevalence of Monoclonal Gammopathy of Undetermined Significance: A study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e45.	0.2	0
1026	Mate pair sequencing outperforms fluorescence in situ hybridization and improves diagnostic yield in the genomic characterization of multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e58.	0.2	0

#	ARTICLE	IF	CITATIONS
1027	A Hematopoietic Score Predicts Survival in Newly Diagnosed Multiple Myeloma Patients.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e85-e86.	0.2	0
1028	Pilot study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with POEMS Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e311-e312.	0.2	0
1029	Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e301-e302.	0.2	0
1030	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e541.	5.1	0
1031	Lymphoma-like double-hit genetic abnormalities (<i>MYC/IGH</i> and <i>IGH/BCL2</i>) in a case of non-secretory multiple myeloma. Leukemia and Lymphoma, 2021, 62, 243-246.	0.6	0
1032	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e710-e713.	0.2	0
1033	Daratumumab for post-ASCT maintenance treatment of myeloma. Lancet Oncology, The, 2021, 22, 1345-1347.	5.1	0
1034	Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma. Touch Reviews in Oncology & Haematology, 2021, 17, 48.	0.1	0
1035	Clinical and Biological Correlates of CD45 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma.. Blood, 2004, 104, 3362-3362.	0.6	0
1036	Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2351-2351.	0.6	0
1037	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. Blood, 2004, 104, 928-928.	0.6	0
1038	Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.. Blood, 2006, 108, 3500-3500.	0.6	0
1039	Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vivo Activity in a Mouse Model of Myeloma.. Blood, 2006, 108, 3487-3487.	0.6	0
1040	Apoptosis Rates in Myeloma Cells Can Be Significantly Affected by CD138 Sorting and by the Specific Method Used To Detect Apoptotic Cells.. Blood, 2006, 108, 3442-3442.	0.6	0
1041	Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma.. Blood, 2006, 108, 3464-3464.	0.6	0
1042	Outcome of patients relapsing early after autologous stem cell transplantation for multiple myeloma. Journal of Clinical Oncology, 2007, 25, 8022-8022.	0.8	0
1043	Prevention of active multiple myeloma (MM) using IL-1 receptor antagonist (IL-1ra) and low-dose dexamethasone (Dex) and monitoring the high sensitivity C-reactive protein (hsCRP). Journal of Clinical Oncology, 2007, 25, 8105-8105.	0.8	0
1044	Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceding Plasma Cell Disorders.. Blood, 2007, 110, 945-945.	0.6	0

#	ARTICLE	IF	CITATIONS
1045	Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma. , 2008, , 279-288.		0
1046	Serum Immunoglobulin Free Light Chain in Primary Amyloidosis: Prognostic Value and Correlations with Clinical Features. Blood, 2008, 112, 2733-2733.	0.6	0
1047	Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. Blood, 2008, 112, 2769-2769.	0.6	0
1048	Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM). Journal of Clinical Oncology, 2009, 27, 8587-8587.	0.8	0
1049	Natural history of multiple myeloma (MM) relapsing after autologous stem cell transplantation (ASCT). Journal of Clinical Oncology, 2009, 27, e19513-e19513.	0.8	0
1050	Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. Journal of Clinical Oncology, 2009, 27, 7039-7039.	0.8	0
1051	Impact of dexamethasone responsiveness on long-term outcome in patients with newly diagnosed myeloma. Journal of Clinical Oncology, 2009, 27, 8603-8603.	0.8	0
1052	Abstract 1796: Significant in-vitro anti-myeloma activity of a novel Akt inhibitor MK2206. , 2010, , .		0
1053	Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2010, 28, 8002-8002.	0.8	0
1054	Overall survival (OS) and time to failure (TTF) associated with anti-myeloma therapy in a U.S. managed-care population.. Journal of Clinical Oncology, 2010, 28, e18505-e18505.	0.8	0
1055	Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR).. Journal of Clinical Oncology, 2010, 28, e18533-e18533.	0.8	0
1056	Prognostic Factors and Risk Stratification in Myeloma. Emerging Cancer Therapeutics, 2010, 1, 299-317.	0.1	0
1057	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. Blood, 2010, 116, 1965-1965.	0.6	0
1058	Mechanism of Action of a Novel c-Met Inhibitor MK2461 In Multiple Myeloma. Blood, 2010, 116, 4078-4078.	0.6	0
1059	Significant In Vitro Activity of a Novel Inhibitor of Apoptosis (IAP) Inhibitor LC161 In Multiple Myeloma. Blood, 2010, 116, 2998-2998.	0.6	0
1060	Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR).. Journal of Clinical Oncology, 2011, 29, 2019-2019.	0.8	0
1061	Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib.. Journal of Clinical Oncology, 2011, 29, e14063-e14063.	0.8	0
1062	Generation of An Automated Tool for the Identification of Genetics Markers and Signatures in Multiple Myeloma Risk-Stratification. Blood, 2011, 118, 2881-2881.	0.6	0

#	ARTICLE	IF	CITATIONS
1063	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. Blood, 2011, 118, 3101-3101.	0.6	0
1064	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. Blood, 2011, 118, 2992-2992.	0.6	0
1065	Racial Disparities in Cytogenetic Characteristics and Outcome of Multiple Myeloma. Blood, 2011, 118, 1808-1808.	0.6	0
1066	Abstract 5562: Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib. , 2012, , .		0
1067	Abstract 5485: Increased prevalence of light chain monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of individuals with multiple myeloma or MGUS. , 2012, , .		0
1068	Does stage migration exist in active multiple myeloma (MM)?. Journal of Clinical Oncology, 2012, 30, 8105-8105.	0.8	0
1069	Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent.. Blood, 2012, 120, 2948-2948.	0.6	0
1070	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. Blood, 2012, 120, 934-934.	0.6	0
1071	Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells.. Blood, 2012, 120, 2943-2943.	0.6	0
1072	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. Blood, 2012, 120, 2059-2059.	0.6	0
1073	Newer IMiDs. , 2013, , 181-213.		0
1074	Approach to Relapsed Refractory Myeloma. , 2014, , 95-100.		0
1075	New Agents for Multiple Myeloma. , 2014, , 131-140.		0
1076	Molecular Classification and Risk Stratification. , 2014, , 55-64.		0
1077	Development Of Solid Malignancies In Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS): A Population-Based Study Of 17,315 Patients. Blood, 2013, 122, 3134-3134.	0.6	0
1078	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. Blood, 2013, 122, 754-754.	0.6	0
1079	Responsiveness Of Cytogenetically Discrete Human Myeloma Cell Lines To Lenalidomide: Lack Of Correlation With Cereblon and Interferon Regulatory Factor 4 Expression Levels. Blood, 2013, 122, 1962-1962.	0.6	0
1080	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). Blood, 2013, 122, 1854-1854.	0.6	0

#	ARTICLE	IF	CITATIONS
1081	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. Blood, 2013, 122, 1842-1842.	0.6	0
1082	Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma.. Journal of Clinical Oncology, 2014, 32, 8595-8595.	0.8	0
1083	Outcomes after relapse from first autologous stem cell transplantation in multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8598-8598.	0.8	0
1084	ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCIâ–Trial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWC) scoring models.. Journal of Clinical Oncology, 2014, 32, 8600-8600.	0.8	0
1085	Abstract 5078: Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. , 2014, , .		0
1086	Abstract 272: Evidence of decreased prevalence of the t(11;14) translocation in black patients with multiple myeloma: A multi-center study. , 2014, , .		0
1087	Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy. Blood, 2014, 124, 3456-3456.	0.6	0
1088	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. Blood, 2014, 124, 4780-4780.	0.6	0
1089	Exome Sequencing in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Families Identifies Cosegregating Functional Variants. Blood, 2014, 124, 1967-1967.	0.6	0
1090	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. Blood, 2014, 124, 4751-4751.	0.6	0
1091	Overcoming Resistance to Apoptosis in Multiple Myeloma By Simultaneous Inhibition of Bcl2 and IAP Families of Anti-Apoptotic Proteins. Blood, 2014, 124, 2088-2088.	0.6	0
1092	Progression and Outcome in Patients with Biclinal Gammopathies. Blood, 2014, 124, 5699-5699.	0.6	0
1093	Clinical outcomes in t(11;14) multiple myeloma.. Journal of Clinical Oncology, 2015, 33, 8592-8592.	0.8	0
1094	Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).. Journal of Clinical Oncology, 2015, 33, 8595-8595.	0.8	0
1095	Survival trends in young patients with Waldenstrom macroglobulinemia (WM).. Journal of Clinical Oncology, 2015, 33, 8596-8596.	0.8	0
1096	Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors. Blood, 2015, 126, 4249-4249.	0.6	0
1097	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	0.6	0
1098	Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. Blood, 2015, 126, 5322-5322.	0.6	0

#	ARTICLE	IF	CITATIONS
1099	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. <i>Blood</i> , 2015, 126, 3039-3039.	0.6	0
1100	Demographic Differences Between Unselected Patients and Participants of Multiple Myeloma Clinical Trials in the US: A Threat to External Validity. <i>Blood</i> , 2015, 126, 634-634.	0.6	0
1101	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4176-4176.	0.6	0
1102	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Blood</i> , 2015, 126, 3044-3044.	0.6	0
1103	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8033-8033.	0.8	0
1104	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8053-8053.	0.8	0
1105	Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7546-7546.	0.8	0
1106	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8062-8062.	0.8	0
1107	Plasma Cell Leukemia. , 2017, , 1-16.		0
1108	Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype. <i>Blood</i> , 2016, 128, 4425-4425.	0.6	0
1109	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5615-5615.	0.6	0
1110	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 996-996.	0.6	0
1111	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016, 128, 3273-3273.	0.6	0
1112	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	0.6	0
1113	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016, 128, 3306-3306.	0.6	0
1114	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	0.6	0
1115	Areas of Consensus and Differences Among a Panel of Experts on the Optimal Use of Newly Approved Agents to Treat Multiple Myeloma (MM): Results from an Annually Updated Online Decision Support Tool. <i>Blood</i> , 2016, 128, 2379-2379.	0.6	0
1116	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3338-3338.	0.6	0

#	ARTICLE	IF	CITATIONS
1117	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016, 128, 3255-3255.	0.6	0
1118	Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	0.6	0
1119	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2187-2187.	0.6	0
1120	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2267-2267.	0.6	0
1121	The use of proteasome inhibitors among patients with POEMS syndrome.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19530-e19530.	0.8	0
1122	Impact of metformin use in the outcomes of multiple myeloma patients post stem cell transplant.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8034-8034.	0.8	0
1123	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8049-8049.	0.8	0
1124	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8047-8047.	0.8	0
1125	Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8020-8020.	0.8	0
1126	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19532-e19532.	0.8	0
1127	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8032-8032.	0.8	0
1128	Treatment approaches and outcomes in extramedullary plasmacytomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8050-8050.	0.8	0
1129	Abstract 1319: Epigenome-wide association study reveals differential DNA methylation consistent with progression of multiple myeloma. , 2017, , .		0
1130	Personalizing MM Treatment: Gaps in Current Knowledge. , 2018, , 169-178.		0
1131	Early Intervention in Multiple Myeloma—Exploring New Frontiers. <i>Oncology &amp; Hematology Review</i> , 2018, 14, 12.	0.2	0
1132	Tandem high-dose chemotherapy and autologous hematopoietic stem cell transplantation (SCT) compared to single SCT for relapsed/refractory germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 572-572.	0.8	0
1133	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8023-8023.	0.8	0
1134	Predictors of disease progression in smoldering Waldenström macroglobulinemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7571-7571.	0.8	0



#	ARTICLE	IF	CITATIONS
1135	Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2018, 36, e20049-e20049.	0.8	0
1136	Abstract 3909: HDAC inhibition in combination with MEK or BCL-2 inhibition as novel therapeutic strategies in multiple myeloma. , 2018, , .		0
1137	Abstract 655: Hyperdiploidy in plasma cell disorders using multi-parametric flow cytometry (MFC) vs. FISH. , 2018, , .		0
1138	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
1139	Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry. Blood, 2018, 132, 4458-4458.	0.6	0
1140	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	0.6	0
1141	Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. Blood, 2018, 132, 3182-3182.	0.6	0
1142	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	0.6	0
1143	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
1144	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	0.6	0
1145	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
1146	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0
1147	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	0.6	0
1148	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	0.6	0
1149	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	0.6	0
1150	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	0.6	0
1151	Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families. Blood, 2018, 132, 4501-4501.	0.6	0
1152	Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM). Blood, 2018, 132, 5664-5664.	0.6	0

#	ARTICLE	IF	CITATIONS
1153	Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting. <i>Blood</i> , 2018, 132, 3253-3253.	0.6	0
1154	Early Intervention in Smoldering Myeloma. <i>Oncology &amp; Hematology Review</i> , 2019, 15, 14.	0.2	0
1155	Cost-effectiveness of once weekly carfilzomib 70 mg/m <sup>2</sup> plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18356-e18356.	0.8	0
1156	Abstract 2686: Associations between a polygenic risk score and risk of multiple myeloma and its precursor. , 2019, , .		0
1157	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. <i>American Journal of Cancer Research</i> , 2021, 11, 3285-3293.	1.4	0
1158	Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1347-1350.	2.3	0
1159	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
1160	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
1161	Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0